Sökning: id:"swepub:oai:DiVA.org:liu-16854" >
Accuracy of Combine...
Accuracy of Combined Protein Gene Product 9.5 and Parafibromin Markers for Immunohistochemical Diagnosis of Parathyroid Carcinoma
-
- Howell, Viive M (författare)
- University of Sydney
-
- Clarkson, Adele (författare)
- University of Sydney
-
- Nelson, Anne E (författare)
- CSIRO, Australia
-
visa fler...
-
- Delbridge, Leigh W (författare)
- University of Sydney
-
- Robinson, Bruce G (författare)
- Van Andel Research Institute
-
- Gimm, Oliver (författare)
- Östergötlands Läns Landsting,Operationskliniken US,Landstinget i Östergötland
-
- Marsh, Deborah J (författare)
- University of Sydney
-
visa färre...
-
(creator_code:org_t)
- The Endocrine Society, 2009
- 2009
- Engelska.
-
Ingår i: JOURNAL OF CLINICAL ENDOCRINOLOGY and METABOLISM. - : The Endocrine Society. - 0021-972X .- 1945-7197. ; 94:2, s. 434-441
- Relaterad länk:
-
https://academic.oup...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Context: Parafibromin, encoded by HRPT2, is the first marker with significant benefit in the diagnosis of parathyroid carcinoma. However, because parafibromin is only involved in up to 70% of parathyroid carcinomas and loss of parafibromin immunoreactivity may not be observed in all cases of HRPT2 mutation, a complementary marker is needed. Objective: We sought to determine the efficacy of increased expression of protein gene product 9.5 (PGP9.5), encoded by ubiquitin carboxyl-terminal esterase L1 (UCHL1) as an additional marker to loss of parafibromin immunoreactivity for the diagnosis of parathyroid carcinoma. Design: In total, 146 parathyroid tumors and nine normal tissues were analyzed for the expression of parafibromin and PGP9.5 by immunohistochemistry and for UCHL1 by quantitative RT-PCR. These samples included six hyperparathyroidism-jaw tumor syndrome-related tumors and 24 sporadic carcinomas. Results: In tumors with evidence of malignancy, strong staining for PGP9.5 had a sensitivity of 78% for the detection of parathyroid carcinoma and/or HRPT2 mutation and a specificity of 100%. Complete lack of nuclear parafibromin staining had a sensitivity of 67% and a specificity of 100%. PGP9.5 was positive in a tumor with the HRPT2 mutation L64P that expressed parafibromin. Furthermore, UCHL1 was highly expressed in the carcinoma/hyperparathyroidism-jaw tumor syndrome group compared to normal (P < 0.05) and benign specimens (P < 0.001). Conclusion: These results suggest that positive staining for PGP9.5 has utility as a marker for parathyroid malignancy, with a slightly superior sensitivity (P = 0.03) and similar high specificity to that of parafibromin.
Nyckelord
- MEDICINE
- MEDICIN
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas